Pharmaceutical Patent Term Extensions – The Only Specialized Forum on SPCs and Patent Protection in Europe and Around the World

June 25 - 26, 2019 | Munich, Germany

TO REGISTER, CLICK HERE »

You can save an extra 10% off the current rate by using code D10-999-JDS19.

Join leading SPC authorities as they address crucial milestones for the application and enforcement of patent term extensions in Europe and throughout the world.

This year’s C5’s Pharma Patent Term Extensions Forum arrives at a critical time for the pharmaceutical industry. Overarching developments from the Teva U.K. decision (C-121/17) to the SPC Manufacturing Waiver and the most recent CJEU Abraxis decision are expected to have a significant impact on the future of the pharmaceutical and biotech industries.

Be part of an exclusive gathering of leading in-house IP counsel, patent attorneys, representatives from multi-jurisdiction patent offices and policy authorities from around the globe who will share their insights on the complexities of SPCs and other types of patent extensions. They will provide you with comprehensive knowledge to ensure that you are leading the way in patent protection for your company and clients.

Download the conference agenda here »

DISINGUISHED CO-CHAIRS:

	Dr. Christian Drescher Head of Patent Affairs Midas Pharma
	Robin Ellis Head Patents – IP Product Strategy Sandoz

EXCLUSIVE IN-HOUSE INSIGHTS FROM:

In-depth Perspectives from Representatives of the following Patent Authorities:

Alfonso Callez-Sanchez

Policy Officer

European Commission

	Dr Oliver Werner Head of SPC Working Group at German Patent and Trade Mark Office
	Pierre Treichel International Legal Affairs at European Patent Office
	Dr. Martijn de Lange Patent Examiner at Netherlands Patent Office
	Inês Cristóvão da Silva Head of Patent and Utility Model Department at Instituto Nacional da Propriedade Industrial

Meet All the Speakers »

New Sessions for 2019:

• Supplementary Protection Certificate Regulation Article 3(a) and (d): Exploring questions of derivatives and the scope of SPC legitimacy.
• The Practical aftermath of the Teva U.K. decision (C-121/17)
• European Commission amendments to the SPC regulation for medicinal products (EC) 469/2009 of 6 May 2009)
• The Imminent arrival of SPC / PTE in China
• SPC eligibility for new formulations of old drugs in Europe in light of the CJEU decision on Art. 3(d) in Abraxis
• Post Brexit Effect on the legalities and enforcement of SPC
• Developments in the U.S affecting patent term extension (PTE) and patent term adjustment (PTA)

THE CONFERENCE WILL PROVIDE INSIGHTS ON ALL THIS AND OTHER KEY CHALLENGES!

REGISTER NOW and save an extra 10% off the conference by using code D10-999-JDS19.

*Discount is valid for new registration only.